Get started
Summit Therapeutics Inc.Summit Therapeutics Inc.Summit Therapeutics Inc.

Summit Therapeutics Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

SMMT chart


Full chart

SMMT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪13.43 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.28 USD
Net income (FY)
‪−614.93 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪114.59 M‬
Beta (1Y)
4.19

Employees


Employees (FY)
105
Change (1Y)
+28 +36.36%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−5.86 M‬ USD

About Summit Therapeutics Inc.


Sector
Health Technology
Industry
Biotechnology
Headquarters
Miami
Website
smmttx.com
Founded
2003
FIGI
BBG00X3GQL76
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SMMT news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SMMT is 17.80 USD — it has decreased by −2.25% in the past 24 hours. Watch Summit Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Summit Therapeutics Inc. stocks are traded under the ticker SMMT.
SMMT stock has fallen by −0.95% compared to the previous week, the month change is a −6.76% fall, over the last year Summit Therapeutics Inc. has showed a 524.56% increase.
We've gathered analysts' opinions on Summit Therapeutics Inc. future price: according to them, SMMT price has a max estimate of 44.00 USD and a min estimate of 23.00 USD. Watch SMMT chart and read a more detailed Summit Therapeutics Inc. stock forecast: see what analysts think of Summit Therapeutics Inc. and suggest that you do with its stocks.
SMMT reached its all-time high on Sep 16, 2024 with the price of 33.89 USD, and its all-time low was 0.66 USD and was reached on Dec 2, 2022. View more price dynamics on SMMT chart.
See other stocks reaching their highest and lowest prices.
SMMT stock is 3.88% volatile and has beta coefficient of 4.19. Track Summit Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Summit Therapeutics Inc. there?
Today Summit Therapeutics Inc. has the market capitalization of ‪13.42 B‬, it has increased by 11.90% over the last week.
Yes, you can track Summit Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Summit Therapeutics Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
SMMT earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.07 USD resulting in a 25.10% surprise. The estimated earnings for the next quarter are −0.08 USD per share. See more details about Summit Therapeutics Inc. earnings.
Summit Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
SMMT net income for the last quarter is ‪−56.25 M‬ USD, while the quarter before that showed ‪−60.38 M‬ USD of net income which accounts for 6.84% change. Track more Summit Therapeutics Inc. financial stats to get the full picture.
No, SMMT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 105.00 employees. See our rating of the largest employees — is Summit Therapeutics Inc. on this list?
Like other stocks, SMMT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Summit Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Summit Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Summit Therapeutics Inc. stock shows the buy signal. See more of Summit Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.